This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter       

Oncology

18
AI study reveals prostate cancer consists of two distinct subtypes
AI study reveals prostate cancer consists of two distinct subtypes
Read more
Cilta-cel gains positive CHMP opinion as second-line R/R multiple myeloma treatment
Cilta-cel gains positive CHMP opinion as second-line R/R multiple myeloma treatment
Read more
Feasibility of using online search data to detect malignancy confirmed by first-of-its-kind study
Feasibility of using online search data to detect malignancy confirmed by first-of-its-kind study
Read more
Significant proportion of oncology drugs have ‘little or no added benefit’, research finds
Significant proportion of oncology drugs have ‘little or no added benefit’, research finds
Read more
HLA-II heterozygosity associated with reduced lung cancer risk in smokers
HLA-II heterozygosity associated with reduced lung cancer risk in smokers
Read more
Three NSCLC indications included in positive CHMP opinion for tislelizumab
Three NSCLC indications included in positive CHMP opinion for tislelizumab
Read more
Synthetic lipid derived from olive shows early promise for glioblastoma patients
Synthetic lipid derived from olive shows early promise for glioblastoma patients
Read more
Combination treatment with arginine-depleting agent improves pleural mesothelioma survival
Combination treatment with arginine-depleting agent improves pleural mesothelioma survival
Read more
Harnessing the potential of bispecific antibodies in blood cancer care and beyond
Harnessing the potential of bispecific antibodies in blood cancer care and beyond
Read more
Momelotinib approved by MHRA for use in myelofibrosis patients with anaemia
Momelotinib approved by MHRA for use in myelofibrosis patients with anaemia
Read more
Global cancer burden ‘rapidly growing’ says WHO as England launches national gene testing
Global cancer burden ‘rapidly growing’ says WHO as England launches national gene testing
Read more
Epcoritamab recommended by NICE for diffuse large B-cell lymphoma after two or more lines of treatment
Epcoritamab recommended by NICE for diffuse large B-cell lymphoma after two or more lines of treatment
Read more
Talazoparib recommended by NICE for advanced breast cancer after initial rejection
Talazoparib recommended by NICE for advanced breast cancer after initial rejection
Read more
Compelling evidence for use of whole genome sequencing in standard cancer care
Compelling evidence for use of whole genome sequencing in standard cancer care
Read more
SC atezolizumab gains EU marketing authorisation for multiple cancer types
SC atezolizumab gains EU marketing authorisation for multiple cancer types
Read more
Blood protein test could ‘kickstart’ new generation of early cancer detection
Blood protein test could ‘kickstart’ new generation of early cancer detection
Read more
Bevacizumab plus chemotherapy shown to improve paediatric neuroblastoma outcomes
Bevacizumab plus chemotherapy shown to improve paediatric neuroblastoma outcomes
Read more
PARP inhibitor talazoparib combined with enzalutamide approved in EU for prostate cancer
PARP inhibitor talazoparib combined with enzalutamide approved in EU for prostate cancer
Read more

Popular articles

Genetic link between pancreatitis risk and GLP-1 medicines to be investigated
Research, consensus and progress in fighting TB: ESCMID Global insights
Patient access to trusted health information a focus of NHS 10-year plan



 
FOLLOW US

IMPORTANT LINKS

MORE FROM COGORA

© Cogora 2025
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x